Modality
Gene Editing
MOA
FcRni
Target
BCL-2
Pathway
JAK/STAT
Ewing Sarcoma
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
~Oct 2020
→ ~Jan 2022
Phase 3
Apr 2022
→ Oct 2030
Phase 3Current
NCT05395433
2,457 pts·Ewing Sarcoma
2023-06→2030-10·Completed
NCT06157785
2,995 pts·Ewing Sarcoma
2022-04→2025-04·Active
5,452 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2211mo agoPh3 Readout· Ewing Sarcoma
2030-10-174.5y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Active
P3
Complet…
Catalysts
Ph3 Readout
2025-04-22 · 11mo ago
Ewing Sarcoma
Ph3 Readout
2030-10-17 · 4.5y away
Ewing Sarcoma
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05395433 | Phase 3 | Ewing Sarcoma | Completed | 2457 | FEV1 |
| NCT06157785 | Phase 3 | Ewing Sarcoma | Active | 2995 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 |